Author:
Pikl Špela,Carrillo Rincón Andrés Felipe,Slemc Lucija,Goranovič Dušan,Avbelj Martina,Gjuračić Krešimir,Sucipto Hilda,Stare Katja,Baebler Špela,Šala Martin,Guo Meijin,Luzhetskyy Andriy,Petković Hrvoje,Magdevska Vasilka
Abstract
Abstract
Background
Natural products are a valuable source of biologically active compounds that have applications in medicine and agriculture. One disadvantage with natural products is the slow, time-consuming strain improvement regimes that are necessary to ensure sufficient quantities of target compounds for commercial production. Although great efforts have been invested in strain selection methods, many of these technologies have not been improved in decades, which might pose a serious threat to the economic and industrial viability of such important bioprocesses.
Results
In recent years, introduction of extra copies of an entire biosynthetic pathway that encodes a target product in a single microbial host has become a technically feasible approach. However, this often results in minor to moderate increases in target titers. Strain stability and process reproducibility are the other critical factors in the industrial setting. Industrial Streptomyces rimosus strains for production of oxytetracycline are one of the most economically efficient strains ever developed, and thus these represent a very good industrial case. To evaluate the applicability of amplification of an entire gene cluster in a single host strain, we developed and evaluated various gene tools to introduce multiple copies of the entire oxytetracycline gene cluster into three different Streptomyces rimosus strains: wild-type, and medium and high oxytetracycline-producing strains. We evaluated the production levels of these engineered S. rimosus strains with extra copies of the oxytetracycline gene cluster and their stability, and the oxytetracycline gene cluster expression profiles; we also identified the chromosomal integration sites.
Conclusions
This study shows that stable and reproducible increases in target secondary metabolite titers can be achieved in wild-type and in high oxytetracycline-producing strains, which always reflects the metabolic background of each independent S. rimosus strain. Although this approach is technically very demanding and requires systematic effort, when combined with modern strain selection methods, it might constitute a very valuable approach in industrial process development.
Funder
Javna Agencija za Raziskovalno Dejavnost RS
Ministrstvo za visoko šolstvo, znanost in tehnologijo
ERA-Co Biotech, NISSION
Publisher
Springer Science and Business Media LLC
Subject
Applied Microbiology and Biotechnology,Bioengineering,Biotechnology
Reference48 articles.
1. Barka EA, Vatsa P, Sanchez L, Gaveau-Vaillant N, Jacquard C, Klenk H-P, et al. Taxonomy, Physiology, and Natural Products of Actinobacteria. Microbiol Mol Biol Rev. 2016;80(1):1–43.
2. Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015 Feb;14(2):111–29.
3. Sanchez S, Rodríguez-Sanoja R, Ramos A, Demain AL. Our microbes not only produce antibiotics, they also overproduce amino acids. J Antibiot 2017;71:26–36.
4. Martens E, Demain AL. The antibiotic resistance crisis, with a focus on the United States. J Antibiot 2017;70(5):520–6.
5. Demain AL, Adrio JL. Strain improvement for production of pharmaceuticals and other microbial metabolites by fermentation. Prog drug Res Fortschritte der Arzneimittelforschung Prog des Rech Pharm. 2008;65:251,253-89.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献